Quick Answer
CORCEPT THERAPEUTICS INC reported Operating Income Loss of $44.80 million for the year ending 2025.
- CORCEPT THERAPEUTICS INC showed a decrease of -67.3% in Operating Income Loss from 2024 to 2025.
- This data is from CORCEPT THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$6.45 million | Q3 2010: -$7.11 million | Q1 2011: -$7.10 million | Q2 2011: -$8.87 million | Q3 2011: -$6.44 million | Q1 2012: -$11.03 million | Q2 2012: -$7.59 million | Q3 2012: -$7.67 million | Q1 2013: -$10.94 million | Q2 2013: -$10.78 million | Q3 2013: -$9.74 million | Q1 2014: -$12.86 million | Q2 2014: -$6.58 million | Q3 2014: -$5.10 million | Q1 2015: -$4.03 million | Q2 2015: -$1.17 million | Q3 2015: $102.0 thousand | Q1 2016: $592.0 thousand | Q2 2016: $1.51 million | Q3 2016: $3.07 million | Q1 2017: $4.74 million | Q2 2017: $12.80 million | Q3 2017: $13.62 million | Q1 2018: $21.00 million | Q2 2018: $20.63 million | Q3 2018: $22.97 million | Q1 2019: $18.96 million | Q2 2019: $24.63 million | Q3 2019: $33.00 million | Q1 2020: $37.71 million | Q2 2020: $35.26 million | Q3 2020: $24.72 million | Q1 2021: $19.64 million | Q2 2021: $31.94 million | Q3 2021: $36.23 million | Q1 2022: $26.77 million | Q2 2022: $31.43 million | Q3 2022: $31.93 million | Q1 2023: $14.85 million | Q2 2023: $29.58 million | Q3 2023: $31.18 million | Q1 2024: $29.50 million | Q2 2024: $35.59 million | Q3 2024: $46.60 million | Q1 2025: $3.42 million | Q2 2025: $26.68 million | Q3 2025: $10.22 million.
- Over the full 17 years of available data (2009 to 2025), CORCEPT THERAPEUTICS INC's Operating Income Loss has grown by 321.2%.
- Historical annual values: Fiscal year 2025: $44.80 million | Fiscal year 2024: $136.95 million | Fiscal year 2023: $107.28 million | Fiscal year 2022: $112.63 million | Fiscal year 2021: $124.48 million | Fiscal year 2020: $128.20 million | Fiscal year 2019: $111.61 million | Fiscal year 2018: $89.50 million | Fiscal year 2017: $52.86 million | Fiscal year 2016: $10.18 million | Fiscal year 2015: -$3.44 million | Fiscal year 2014: -$27.62 million | Fiscal year 2013: -$41.50 million | Fiscal year 2012: -$36.27 million | Fiscal year 2011: -$32.33 million | Fiscal year 2010: -$27.44 million | Fiscal year 2009: -$20.25 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: